i2i Academy
From Idea to IND
A half-day educational forum for teams advancing mammalian biologics and ADCs toward the clinic.
Join Lonza experts, industry leaders and fellow biotech innovators for an afternoon of practical insights, real-world experiences and meaningful connections. Focused on mammalian biologics and antibody-drug conjugates (ADCs), the program will explore key considerations across drug substance and drug product, including CMC, manufacturability, formulation and regulatory strategy.
3 Reasons to Attend i2i Academy
Learn from industry experts
Through case studies, fireside discussions and interactive sessions, gain practical insights to help inform critical development decisions and accelerate your path to clinic.
Experience state-of-the-art facilities
Take an exclusive tour of Lonza's drug product development facilities, including formulation, process development, preclinical manufacturing and particle analysis laboratories.
Build your biotech network
Continue the conversation during an evening networking reception in Basel and build valuable connections across the biotech ecosystem.
What to expect
✓ Expert presentations on key IND-enabling considerations
✓ Industry case studies and lessons learned
✓ Interactive discussions with leaders across the biotech ecosystem
✓ Exclusive tour of Lonza's drug product development facilities
✓ Networking with peers, partners and industry experts
Date
Monday, 12 October 2026
Timing
i2i Academy: 13:00–17:30 CEST
Evening Networking Reception: 18:00–21:30 CEST
Location
Stücki Technology Park
Hochbergerstrasse 60
4057 Basel, Switzerland
Please complete the form to register your interest
Event agenda
Start | End Time | Event | Location |
|---|---|---|---|
12:30 | 13:00 | Registration (including light food/beverages) | Mini building F cafeteria |
13:00 | 13:10 | Welcome | |
13:10 | 13:40 | Decision #1: Is your molecule ready to move forward? De-risking and optimizing candidates before development begins | |
13:40 | 14:10 | Decision #2: What is your IND strategy? Building an efficient and scalable path to IND | |
14:10 | 14:40 | Decision #3: How do you resource the journey? What investors look for before IND: data, risk and development readiness | |
14:40 | 15:00 | Networking break + refreshments | Mini building F cafeteria |
15:00 | 15:20 | Decision #4: Are you generating the right data? Analytical and CMC considerations that support a successful IND | |
15:20 | 15:40 | Technology spotlight: ADCs in focus Key considerations for next-generation bioconjugates on the path to IND | |
15:40 | 16:00 | Decision #5: Are you ready for submission? CMC and regulatory considerations that can make or break an IND |
16:00 | 16:05 | Transport to Building G | |
16:00 | 16:55 | Facility tour / poster session / networking (light food, refreshments) | Building G cafeteria |
16:55 | 17:00 | Transport to Building F | |
17:00 | 17:10 | Customer success story | |
17:10 | 17:30 | Panel discussion | |
17:30 | 18:00 | Travel to networking reception |
Meet the experts
Eddy Berthier
Principal Scientist
Drug Product Services
Raymond Donninger
Senior Director
Commercial Development
Rebecca Michael
Head of Cell and Molecular Biology
Integrated Biologics
James Berrie
Technical Director
CMC Strategy & Process Development
Tobias Brandmann
Head Process Development
Bioconjugates
Sabrina Vollers
Associate Director, Global Analytics Senior Technical CMC Lead
